O	0	9	Selecting
O	10	13	the
O	14	21	optimal
O	22	30	position
O	31	33	of
B-intervention	34	38	CDK4
I-intervention	38	39	/
I-intervention	39	40	6
I-intervention	41	51	inhibitors
O	52	54	in
O	55	62	hormone
O	63	71	receptor
O	71	72	-
O	72	80	positive
O	81	89	advanced
O	90	96	breast
O	97	103	cancer
O	104	105	-
O	106	109	the
O	110	115	SONIA
O	116	121	study
O	121	122	:
O	123	128	study
O	129	137	protocol
O	138	141	for
O	142	143	a
O	144	154	randomized
O	155	165	controlled
O	166	171	trial
O	171	172	.

O	173	182	Combining
O	183	189	cyclin
O	189	190	-
O	190	199	dependent
O	200	207	kinases
O	208	209	4
O	210	213	and
O	214	215	6
O	216	217	(
O	217	221	CDK4
O	221	222	/
O	222	223	6
O	223	224	)
O	225	235	inhibitors
O	236	240	with
O	241	250	endocrine
O	251	258	therapy
O	259	261	is
O	262	264	an
O	265	274	effective
O	275	283	strategy
O	284	286	to
O	287	294	improve
O	295	306	progression
O	306	307	-
O	307	311	free
O	312	320	survival
O	321	323	in
O	324	331	hormone
O	332	340	receptor
O	340	341	-
O	341	349	positive
O	350	351	(
O	351	353	HR
O	353	354	+
O	354	355	)
O	355	356	,
O	357	362	human
O	363	372	epidermal
O	373	379	growth
O	380	386	factor
O	387	395	receptor
O	396	397	2
O	398	399	(
O	399	403	HER2
O	403	404	)
O	404	405	-
O	405	413	negative
O	414	422	advanced
O	423	429	breast
O	430	436	cancer
O	436	437	.

O	438	443	There
O	444	446	is
O	447	448	a
O	449	453	lack
O	454	456	of
O	457	468	comparative
O	469	473	data
O	474	476	to
O	477	481	help
O	482	492	clinicians
O	493	499	decide
O	500	502	if
O	503	507	CDK4
O	507	508	/
O	508	509	6
O	510	520	inhibitors
O	521	524	can
O	525	529	best
O	530	532	be
O	533	538	added
O	539	541	to
O	542	547	first
O	547	548	-
O	549	551	or
O	552	558	second
O	558	559	-
O	559	563	line
O	564	573	endocrine
O	574	581	therapy
O	581	582	.

O	583	594	Improvement
O	595	597	in
O	598	604	median
O	605	616	progression
O	616	617	-
O	617	621	free
O	622	630	survival
O	631	633	in
O	634	639	first
O	639	640	-
O	640	644	line
O	645	652	studies
O	653	655	is
O	656	662	larger
O	663	667	than
O	668	670	in
O	671	677	second
O	677	678	-
O	678	682	line
O	683	690	studies
O	690	691	,
O	692	695	but
O	696	700	CDK4
O	700	701	/
O	701	702	6
O	703	713	inhibitors
O	714	718	have
O	719	722	not
O	723	735	consistently
O	736	741	shown
O	742	744	to
O	745	752	improve
O	753	760	overall
O	761	769	survival
O	770	772	or
O	773	780	quality
O	781	783	of
O	784	788	life
O	788	789	.

O	790	794	They
O	795	797	do
O	798	802	come
O	803	807	with
O	808	813	added
O	814	822	toxicity
O	823	826	and
O	827	832	costs
O	832	833	,
O	834	837	and
O	838	842	many
O	843	851	patients
O	852	856	have
O	857	864	lasting
O	865	872	disease
O	873	882	remission
O	883	885	on
O	886	895	endocrine
O	896	903	therapy
O	904	909	alone
O	909	910	.

O	911	913	No
O	914	922	subgroup
O	923	926	has
O	927	931	been
O	932	942	identified
O	943	945	to
O	946	952	select
O	953	961	patients
O	962	965	who
O	966	969	are
O	970	974	most
O	975	981	likely
O	982	984	to
O	985	992	benefit
O	993	997	from
O	998	1001	the
O	1002	1010	addition
O	1011	1013	of
O	1014	1018	CDK4
O	1018	1019	/
O	1019	1020	6
O	1021	1031	inhibition
O	1032	1034	in
O	1035	1038	any
O	1039	1043	line
O	1044	1046	of
O	1047	1056	treatment
O	1056	1057	.

O	1058	1068	Altogether
O	1068	1069	,
O	1070	1075	these
O	1076	1083	factors
O	1084	1088	make
O	1089	1093	that
O	1094	1097	the
O	1098	1105	optimal
O	1106	1114	strategy
O	1115	1118	for
O	1119	1124	using
O	1125	1129	CDK4
O	1129	1130	/
O	1130	1131	6
O	1132	1142	inhibitors
O	1143	1145	in
O	1146	1154	clinical
O	1155	1163	practice
O	1164	1166	is
O	1167	1174	unknown
O	1174	1175	.

O	1176	1179	The
O	1180	1185	SONIA
O	1186	1191	study
O	1192	1194	is
O	1195	1197	an
O	1198	1210	investigator
O	1210	1211	-
O	1211	1220	initiated
O	1220	1221	,
O	1222	1233	multicenter
O	1233	1234	,
O	1235	1245	randomized
O	1246	1251	phase
O	1252	1255	III
O	1256	1261	study
O	1262	1264	in
B-eligibility	1265	1273	patients
I-eligibility	1274	1278	with
I-eligibility	1279	1281	HR
I-eligibility	1281	1282	+
I-eligibility	1282	1283	/
I-eligibility	1283	1287	HER2
I-eligibility	1287	1288	-
I-eligibility	1288	1296	negative
I-eligibility	1297	1305	advanced
I-eligibility	1306	1312	breast
I-eligibility	1313	1319	cancer
O	1319	1320	.

O	1321	1329	Patients
O	1330	1333	are
O	1334	1342	randomly
O	1343	1351	assigned
O	1352	1354	to
O	1355	1362	receive
O	1363	1369	either
O	1370	1378	strategy
O	1379	1380	A
O	1381	1382	(
O	1382	1387	first
O	1387	1388	-
O	1388	1392	line
O	1393	1402	treatment
O	1403	1407	with
O	1408	1409	a
O	1410	1413	non
O	1413	1414	-
O	1414	1423	steroidal
O	1424	1433	aromatase
O	1434	1443	inhibitor
O	1444	1452	combined
O	1453	1457	with
O	1458	1462	CDK4
O	1462	1463	/
O	1463	1464	6
O	1465	1475	inhibition
O	1475	1476	,
O	1477	1485	followed
O	1486	1488	on
O	1489	1500	progression
O	1501	1503	by
O	1504	1515	fulvestrant
O	1515	1516	)
O	1517	1519	or
B-control	1520	1528	strategy
I-control	1529	1530	B
O	1531	1532	(
O	1532	1537	first
O	1537	1538	-
O	1538	1542	line
O	1543	1552	treatment
O	1553	1557	with
O	1558	1559	a
O	1560	1563	non
O	1563	1564	-
O	1564	1573	steroidal
O	1574	1583	aromatase
O	1584	1593	inhibitor
O	1593	1594	,
O	1595	1603	followed
O	1604	1606	on
O	1607	1618	progression
O	1619	1621	by
O	1622	1633	fulvestrant
O	1634	1642	combined
O	1643	1647	with
O	1648	1652	CDK4
O	1652	1653	/
O	1653	1654	6
O	1655	1665	inhibition
O	1665	1666	)
O	1666	1667	.

O	1668	1671	The
O	1672	1679	primary
O	1680	1689	objective
O	1690	1692	is
O	1693	1695	to
O	1696	1700	test
O	1701	1708	whether
O	1709	1717	strategy
O	1718	1719	A
O	1720	1722	is
O	1723	1727	more
O	1728	1737	effective
O	1738	1742	than
O	1743	1751	strategy
O	1752	1753	B
O	1753	1754	.

O	1755	1758	The
O	1759	1766	primary
O	1767	1775	endpoint
O	1776	1778	is
B-outcome-Measure	1779	1783	time
I-outcome-Measure	1784	1788	from
I-outcome-Measure	1789	1802	randomization
I-outcome-Measure	1803	1805	to
I-outcome-Measure	1806	1812	second
I-outcome-Measure	1813	1822	objective
I-outcome-Measure	1823	1834	progression
I-outcome-Measure	1835	1836	(
I-outcome-Measure	1836	1840	PFS2
I-outcome-Measure	1840	1841	)
O	1841	1842	.

O	1843	1852	Secondary
O	1853	1862	endpoints
O	1863	1870	include
B-outcome-Measure	1871	1878	overall
I-outcome-Measure	1879	1887	survival
O	1887	1888	,
B-outcome-Measure	1889	1895	safety
O	1895	1896	,
B-outcome-Measure	1897	1904	quality
I-outcome-Measure	1905	1907	of
I-outcome-Measure	1908	1912	life
O	1912	1913	,
O	1914	1917	and
B-outcome-Measure	1918	1922	cost
I-outcome-Measure	1922	1923	-
I-outcome-Measure	1923	1936	effectiveness
O	1936	1937	.

O	1938	1942	Five
O	1942	1943	-
O	1943	1950	hundred
O	1951	1958	seventy
O	1958	1959	-
O	1959	1963	four
O	1964	1970	events
O	1971	1976	yield
O	1977	1979	89
O	1979	1980	%
O	1981	1986	power
O	1987	1989	to
O	1990	1994	show
O	1995	1999	that
O	2000	2008	strategy
O	2009	2010	A
O	2011	2014	has
O	2015	2028	statistically
O	2029	2040	significant
O	2040	2041	,
O	2042	2052	clinically
O	2053	2063	meaningful
O	2064	2072	superior
B-outcome	2073	2077	PFS2
O	2078	2079	(
O	2079	2088	according
O	2089	2091	to
O	2092	2096	ESMO
O	2096	2097	-
O	2097	2101	MCBS
O	2101	2102	)
O	2103	2105	in
O	2106	2107	a
O	2108	2111	log
O	2111	2112	-
O	2112	2116	rank
O	2117	2121	test
O	2122	2124	at
O	2125	2128	the
O	2129	2132	two
O	2132	2133	-
O	2133	2138	sided
O	2139	2141	95
O	2141	2142	%
O	2143	2153	confidence
O	2154	2159	level
O	2159	2160	.

O	2161	2166	Given
O	2167	2169	an
O	2170	2177	accrual
O	2178	2184	period
O	2185	2187	of
O	2188	2190	42
O	2191	2197	months
O	2198	2201	and
O	2202	2204	an
O	2205	2215	additional
O	2216	2218	18
O	2219	2225	months
O	2226	2232	follow
O	2232	2233	-
O	2233	2235	up
O	2235	2236	,
O	2237	2246	inclusion
O	2247	2249	of
O	2250	2254	1050
O	2255	2264	evaluable
O	2265	2273	patients
O	2274	2276	is
O	2277	2285	required
O	2285	2286	.

O	2287	2291	This
O	2292	2297	study
O	2298	2304	design
O	2305	2315	represents
O	2316	2321	daily
O	2322	2330	clinical
O	2331	2339	practice
O	2339	2340	,
O	2341	2344	and
O	2345	2348	the
O	2349	2356	results
O	2357	2361	will
O	2362	2365	aid
O	2366	2376	clinicians
O	2377	2379	in
O	2380	2388	deciding
O	2389	2393	when
O	2394	2400	adding
O	2401	2405	CDK4
O	2405	2406	/
O	2406	2407	6
O	2408	2418	inhibitors
O	2419	2421	to
O	2422	2431	endocrine
O	2432	2439	therapy
O	2440	2444	will
O	2445	2452	benefit
O	2453	2458	their
O	2459	2467	patients
O	2468	2472	most
O	2472	2473	.

O	2474	2484	Additional
O	2485	2494	biomarker
O	2495	2503	analyses
O	2504	2507	may
O	2508	2512	help
O	2513	2515	to
O	2516	2524	optimize
O	2525	2532	patient
O	2533	2542	selection
O	2542	2543	.
O	2544	2548	http
O	2548	2549	:
O	2549	2550	/
O	2550	2551	/
O	2551	2565	clinicaltrials
O	2565	2566	.
O	2567	2570	gov
O	2570	2571	:
O	2572	2583	NCT03425838
O	2584	2585	(
O	2585	2586	8
O	2587	2595	February
O	2596	2600	2018
O	2600	2601	)
O	2601	2602	.

O	2603	2610	EudraCT
O	2610	2611	-
O	2611	2617	number
O	2617	2618	:
O	2619	2623	2017
O	2623	2624	-
O	2624	2630	002334
O	2630	2631	-
O	2631	2633	23
O	2634	2635	(
O	2635	2637	29
O	2638	2647	September
O	2648	2652	2017
O	2652	2653	)
O	2653	2654	.
